Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

Background And Objectives: Bortezomib is a selective proteasome inhibitor which has shown significant activity in a variety of hematologic malignancies including multiple myeloma, mantle cell lymphoma and marginal zone lymphoma. Thus, this agent is worth studying in patients with Waldenström's macroglobulinemia (WM).

Design And Methods: Patients with refractory or relapsed WM were treated with bortezomib administered intravenously at a dose of 1.